Article

Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval process

2026-05-27

Abstract excerpt

<p>In this commentary we review the recent approval of escitalopram for generalized anxiety disorder (GAD) in children and adolescents. We critically discuss the FDA approval document and the approval trial. In the approval trial, efficacy was not clinically meaningful, statistical significance uncertain, and there were significantly more adverse events with escitalopram than with placebo. Relative to placebo, chi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c9728ea8-bac2-5d28-b2d0-db78634d83ff
DOI: 10.31234/osf.io/6fqk4_v3

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processDOI 10.31234/osf.io/6fqk4_v3Read

Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processSemantic proximity Read

The effectiveness of using escitalopram in pediatric generalized anxiety disorder and the methods to predict the treatment response: A systematic review and meta-analysisSemantic proximity Read

Side effect profile and comparative tolerability of newer generation antidepressants in the acute treatment of major depressive disorder in children and adolescents: protocol for a systematic review and network meta-analysisSemantic proximity Read

Emergence of psychiatric adverse events during antipsychotic treatment in naive children and adolescentsSemantic proximity Read

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.Semantic proximity Read

Gastrointestinal Symptoms in Pediatric Patients with Anxiety Disorders and their Relationship to Treatment with Escitalopram or PlaceboSemantic proximity Read

First-generation antihistamine and seizure risk in pediatrics: A call to awarenessSemantic proximity Read

Audit of use of stiripentol in adults with Dravet syndrome.Semantic proximity Read

Improving evidence-based risk-benefit decision-making of medicines for childrenSemantic proximity Read

Safety and Efficacy of Two Doses of Tandospirone Citrate for Generalized Anxiety Disorder: A Multicenter Randomized Controlled TrialSemantic proximity Read

The Prevalence of Generalized Anxiety Disorder Among Adolescent Girls: A Cross-Sectional StudySemantic proximity Read